Catheter Precision Terminates Material Agreement
Ticker: VTAK · Form: 8-K · Filed: Nov 21, 2025 · CIK: 1716621
| Field | Detail |
|---|---|
| Company | Catheter Precision, Inc. (VTAK) |
| Form Type | 8-K |
| Filed Date | Nov 21, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $4.3 million, $4.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: agreement-termination
Related Tickers: CPCI
TL;DR
CPCI terminated a big deal, details scarce.
AI Summary
Catheter Precision, Inc. announced on November 17, 2025, the termination of a material definitive agreement. The company, formerly known as Ra Medical Systems, Inc., filed this 8-K report to disclose this event. No specific details regarding the agreement or the counterparty were provided in the filing.
Why It Matters
The termination of a material definitive agreement can signal significant changes in a company's strategic partnerships or operational plans, potentially impacting future revenue streams or business operations.
Risk Assessment
Risk Level: medium — Termination of a material agreement can introduce uncertainty and potential financial or operational disruptions.
Key Players & Entities
- Catheter Precision, Inc. (company) — Registrant
- Ra Medical Systems, Inc. (company) — Former company name
- November 17, 2025 (date) — Date of earliest event reported
FAQ
What was the specific material definitive agreement that was terminated?
The filing does not specify the details of the material definitive agreement that was terminated.
Who was the counterparty to the terminated agreement?
The filing does not disclose the identity of the other party involved in the terminated agreement.
What is the effective date of the termination?
The earliest event reported is November 17, 2025, which is the date of the report and likely the effective date or announcement date of the termination.
What are the potential financial or operational impacts of this termination on Catheter Precision, Inc.?
The filing does not provide information on the potential impacts of the termination.
Was this termination a result of a breach of contract or a mutual decision?
The filing does not provide information regarding the reasons for the termination.
Filing Stats: 503 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-11-21 16:15:57
Key Financial Figures
- $0.0001 — ch registered Common Stock , par value $0.0001 per share VTAK NYSE American Indica
- $4.3 million — ng an aggregate offering price of up to $4.3 million. The Company is not subject to any term
- $4.0 million — notice, the Company sold approximately $4.0 million of shares of common stock under the ATM
Filing Documents
- vtak20251119_8k.htm (8-K) — 23KB
- 0001437749-25-036000.txt ( ) — 153KB
- vtak-20251117.xsd (EX-101.SCH) — 3KB
- vtak-20251117_def.xml (EX-101.DEF) — 12KB
- vtak-20251117_lab.xml (EX-101.LAB) — 15KB
- vtak-20251117_pre.xml (EX-101.PRE) — 12KB
- vtak20251119_8k_htm.xml (XML) — 3KB
02. Termination of a Material Definitive Agreement
Item 1.02. Termination of a Material Definitive Agreement. On November 17, 2025, Catheter Precision, Inc. (the "Company") delivered notice to terminate its At-Market-Offering Agreement (the "ATM Agreement"), dated as of May 19, 2025, with Ladenburg Thalmann & Co. Inc. (the "Agent") providing for the Company's "atthemarket" equity offering program (the "ATM Program"), to be effective as of November 24, 2025. Pursuant to the ATM Agreement and the prospectus supplements filed for the ATM Program, the Company could offer and sell, from time to time through the Agent, shares of its common stock, par value $0.0001 per share ("common stock"), having an aggregate offering price of up to $4.3 million. The Company is not subject to any termination penalties related to the termination of the ATM Agreement. Prior to the termination notice, the Company sold approximately $4.0 million of shares of common stock under the ATM Program.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CATHETER PRECISION, INC. Date: November 21, 2025 By: /s/ Philip Anderson Philip Anderson Chief Financial Officer